Weekly Recap | Twist Bioscience +3.19%, consensus target below spot
I'm LongbridgeAI, I can summarize articles.Twist Bioscience rose 3.19% this week to $188.67, outperforming the S&P 500 by about 3.46 percentage points. The week saw a wide 13.91% range: Monday dipped to $175.02 before recovering, Wednesday climbed towards $197.19, and Thursday touched a 60-day high of $200.31 intraday before easing back to end the week at $188.67. The overall shape was a choppy advance that faded from its peak.
The Week
Twist Bioscience rose 3.19% this week to $188.67, outperforming the S&P 500 by about 3.46 percentage points. The week saw a wide 13.91% range: Monday dipped to $175.02 before recovering, Wednesday climbed towards $197.19, and Thursday touched a 60-day high of $200.31 intraday before easing back to end the week at $188.67. The overall shape was a choppy advance that faded from its peak.
Key Events
The company itself had no major product, earnings, or regulatory news this week. Instead, the focus sat on price action near record highs. After-hours trading on Monday rose 5.55%, with a pullback following nine consecutive days of new highs. Tuesday marked a fresh one-year high. Wednesday’s pre-market session gained another 3.15% after a target price was raised to $190, pushing the share to a 52-week high. Thursday placed TWST among biotech names hitting 52-week highs. The week’s flow was dominated by momentum headlines rather than company-specific catalysts.
Analyst Ratings
Among the 13 brokers covering Twist Bioscience, 7 rate it buy, 2 overweight, 3 hold, and 1 sell. The consensus rating is buy, with a consensus target price of $120.83, about 36% below spot. The target range is wide, from a low of $36 to a high of $212, signalling sharp disagreement. The stock ranks 81st out of 507 names in the biotech industry by rating.
The Week Ahead
Twist Bioscience has no scheduled earnings or event calendar next week, but macro data is heavy. Monday brings the final U.S. services PMI and ISM non-manufacturing PMI, Tuesday has trade balance figures, and Wednesday includes EIA crude inventory data. Biotech is sensitive to shifts in rates and risk appetite, so these prints could shape sector-wide fund flows.
In Short
Twist Bioscience pushed towards record highs and beat the broader market this week, yet the broker consensus target sits about 36% below spot and the target range is extremely wide, pointing to real disagreement about the long-term path. The latest session faded from its high, leaving macro data and money flows as the key signals for this high-flying sector.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.